What does Catalio Capital Management, LP hold? Q1 2026 13F Holdings & Portfolio

AI Analysis · Q1 2026 · Q1 2026

Catalio Capital Management, LP filed its latest 13F-HR for Q1 2026. See the latest holdings and position changes below.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight

DIANTHUS THERAPEUTICS INC

$47M560K9.8%

BRIDGEBIO PHARMA INC

$32M432K6.7%

ASCENDIS PHARMA A/S

$30M129K6.2%

BRISTOL-MYERS SQUIBB CO

$26M421K5.3%

SYNDAX PHARMACEUTICALS INC

$24M1.0M5.1%

GILEAD SCIENCES INC

$23M164K4.8%

TERNS PHARMACEUTICALS INC

$22M409K4.5%

DEFINIUM THERAPEUTICS INC

$20M1.0M4.1%

SOLENO THERAPEUTICS INC

$19M578K4.0%

BOSTON SCIENTIFIC CORP

$19M299K3.9%

Filing history loading…